Fully-human Monoclonal Antibodies Against Human EphrinB2 and EphB4
Keywords: Research Tools, Monoclonal Antibodies, Ephrin Receptor
The Center for Cancer Research's Nanobiology Program is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize fully-human monoclonal antibodies against human
EphrinB2 and EphB4.
Description of Invention:
Ephrin receptor tyrosine kinases and their ephrin ligands have been
implicated in cancer pathogenesis. Ephrin receptors and ligands
affect tumor growth, invasiveness, angiogenesis, and metastasis.
Ephrin signaling activities in cancer are complex and are only now
beginning to be uncovered.
Researchers at the National Cancer Institute-Frederick, NIH, have
developed a set of five fully-human monoclonal antibodies against
human Ephrin-B2 and Ephrin type-B receptor 4 ("EphB4"). The
antibodies were identified by screening a naive human antibody
phage display library against Ephrin-B2 and EphB4. These human
monoclonal antibodies have high affinity and specificity for
Ephrin-B2 and EphB4.
- Research reagents for in vitro/in vivo investigation of Ephrin
receptor and ligand interactions
- Targeting reagents for in vivo imaging
- Research reagents for protein co-crystallization
- High affinity and antigen specificity
- Bind both soluble ectodomains and cell surface-expressed
Research Material. Patent protection is not being pursued for
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Please reference advertisement #1036
Opportunities available in PDF format require Adobe Reader to view.